IP Library Granted Patent US 11,998,511
Granted Patent B2
US 11,998,511 · App. 17/853,168 · Granted Jun 4, 2024

Methods, compositions, and devices for supplying dietary fatty acid needs

Inventors: Alexey L. Margolin (Newton, MA); Robert Gallotto (Newton, MA); Bhami Shenoy (South Grafton, MA)
Assignee: ALCRESTA THERAPEUTICS, INC.
A61J15/0092A23D7/011A23D7/013A23D9/013A23K20/158A23K50/30A23L29/06A23L33/115A23L33/12A23L33/40A61J15/0003A61J15/0026A61K9/0029A61K31/202A61K38/465B65D1/02B65D41/02B65D81/32B65D85/72C12Y301/00A23V2002/00C12Y301/01
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,998,511
App. No.
17/853,168
Granted
Jun 4, 2024
Kind
B2
Abstract

Nutritional formulas comprising long-chain polyunsaturated fatty acids (LC-PUFAs) are provided, along with methods and devices for preparing and/or administering nutritional formulas. In some embodiments, a percentage of the LC-PUFAs in the nutritional formula are in the form of monoglycerides and/or free fatty acids. In some embodiments, the nutritional formulas do not comprise added lipase. Also provided are methods for providing nutrition to a subject, methods for improving fat absorption, methods for improving cognitive ability, methods for preventing chronic lung disease, and methods for reducing the length of time a patient requires total parenteral nutrition.

Claims (26)

1. A method of providing a nutritional composition to a subject, the method comprising:

receiving a nutritional composition within an enteral feeding device;

exposing the nutritional composition to lipase immobilized within the enteral feeding device, wherein exposing the nutritional composition to the lipase hydrolyzes triglycerides and/or esters within the nutritional composition to form a hydrolyzed nutritional composition; and

delivering the hydrolyzed nutritional composition from the enteral feeding device to the subject,

wherein the method reduces a length of time the subject is on total parenteral nutrition.

2. The method of claim 1 , wherein the subject is diagnosed with at least one of: Alzheimer's disease, bipolar disorder, depression, sepsis, acute respiratory stress, cancer, cardiovascular disease, stroke, Parkinson's disease, schizophrenia, diabetes, multiple sclerosis, malnutrition, impaired GI function, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, short bowel syndrome, irritable bowel disorder, Systemic Inflammatory Response Syndrome, celiac disease, Crohn's disease, Cystic Fibrosis, Zollinger-Ellison syndrome, hypertriglyceridemia, neoplasms, hemochromatosis, primary sclerosing cholangitis, primary biliary cirrhosis, diarrhea, Shwachman's syndrome, trypsinogen deficiency, enterokinase deficiency, chylothorax, isolated deficiency of lipase, premature birth, pancreatic insufficiency, pancreatitis, malabsorption, compromised pancreatic output, a reduced ability to hydrolyze triglycerides or esters, or a reduced ability to absorb triglycerides or esters.

3. The method of claim 1 , wherein the nutritional composition is exposed to the immobilized lipase for at least one minute, prior to delivering the hydrolyzed nutritional composition to the subject.

4. The method of claim 1 , wherein the nutritional composition is exposed to the immobilized lipase for no more than thirty seconds, prior to delivering the hydrolyzed nutritional composition to the subject.

5. The method of claim 1 , wherein the nutritional composition is exposed to the immobilized lipase for no more than one minute, prior to delivering the hydrolyzed nutritional composition to the subject.

6. The method of claim 1 , wherein the nutritional composition is exposed to the immobilized lipase for no more than five minutes, prior to delivering the hydrolyzed nutritional composition to the subject.

7. The method of claim 1 , wherein the nutritional composition is exposed to the immobilized lipase for no more than sixty minutes, prior to delivering the hydrolyzed nutritional composition to the subject.

8. The method of claim 1 , wherein exposing the nutritional composition to the immobilized lipase causes the hydrolyzed nutritional composition to comprise more free fatty acids than monoglycerides.

9. The method of claim 1 , wherein the enteral feeding device includes a syringe.

10. The method of claim 1 , wherein the method further reduces gut atrophy in the subject.

11. A method of providing a nutritional composition to a subject, the method comprising:

receiving a nutritional composition within an enteral feeding device;

exposing the nutritional composition to lipase immobilized within the enteral feeding device, wherein exposing the nutritional composition to the lipase hydrolyzes triglycerides and/or esters within the nutritional composition into monoglycerides and free fatty acids to form a hydrolyzed nutritional composition; and

delivering the hydrolyzed nutritional composition from the enteral feeding device and to the subject,

wherein the method reduces gut atrophy in the subject.

12. The method of claim 11 , wherein the subject is diagnosed with at least one of: Alzheimer's disease, bipolar disorder, depression, sepsis, acute respiratory stress, cancer, cardiovascular disease, stroke, Parkinson's disease, schizophrenia, diabetes, multiple sclerosis, malnutrition, impaired GI function, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, short bowel syndrome, irritable bowel disorder, Systemic Inflammatory Response Syndrome, celiac disease, Crohn's disease, Cystic Fibrosis, Zollinger-Ellison syndrome, hypertriglyceridemia, neoplasms, hemochromatosis, primary sclerosing cholangitis, primary biliary cirrhosis, diarrhea, Shwachman's syndrome, trypsinogen deficiency, enterokinase deficiency, chylothorax, isolated deficiency of lipase, premature birth, pancreatic insufficiency, pancreatitis, malabsorption, compromised pancreatic output, a reduced ability to hydrolyze triglycerides or esters, or a reduced ability to absorb triglycerides or esters.

13. The method of claim 11 , wherein the hydrolyzed nutritional composition is delivered to the subject via a feeding tube.

14. The method of claim 11 , wherein exposing the nutritional composition to the immobilized lipase causes the hydrolyzed nutritional composition to comprise more free fatty acids than monoglycerides.

15. The method of claim 11 , wherein the nutritional composition is exposed to the immobilized lipase for at least one minute, prior to delivering the hydrolyzed nutritional composition to the subject.

16. The method of claim 11 , wherein the nutritional composition is exposed to the immobilized lipase for no more than five minutes, prior to delivering the hydrolyzed nutritional composition to the subject.

17. The method of claim 11 , wherein the nutritional composition is exposed to the immobilized lipase for no more than sixty minutes, prior to delivering the hydrolyzed nutritional composition to the subject.

18. The method of claim 11 , wherein the method further reduces a length of time the subject is on total parenteral nutrition.

Assignments (3)
SECURITY INTEREST Recorded Mar 12, 2024
From: ALCRESTA THERAPEUTICS, INC.
To: TWIN BROOK CAPITAL PARTNERS, LLC, AS AGENT
Reel/Frame 066742/0319 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2022
From: MARGOLIN, ALEXEY L; GALLOTTO, ROBERT; SHENOY, BHAMI
To: ALCRESTA, INC.
Reel/Frame 060907/0079 →
CHANGE OF NAME Recorded Jul 25, 2022
From: ALCRESTA, INC.
To: ALCRESTA THERAPEUTICS, INC.
Reel/Frame 060907/0087 →
Continuity (9)
Continuation 17211487 · Mar 24, 2021
Continuation 16000327 · Jun 5, 2018
Continuation 15684430 · Aug 23, 2017
Continuation 15587513 · May 5, 2017
Continuation 15240596 · Aug 18, 2016
Continuation 14378856
Provisional Application 61719173 · Oct 26, 2012
Provisional Application 61600207 · Feb 17, 2012
Related Publication 20220331208A1 · Oct 20, 2022